Healthcare & Pharmaceuticalscategory Teen in critical condition with Canada's first presumptive ... 2024 Healthcare & Pharmaceuticalscategory Novavax cuts 2024 revenue forecast again on lower ...

The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines, the company said on Monday.

In a media briefing streamed live on Canada's Global News, Bonnie Henry, MD, BC's health officer, shared the latest investigation ... (Schnirring, 11/12) Novavax yesterday announced that the US Food ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...

TD Cowen lowered the firm’s price target on Novavax (NVAX) to $9 from $14 and keeps a Hold rating on the shares. The firm said the FDA lifted its clinical hold on its COVID/flu combo and standalone ...

Cambridge: Moderna, Inc. has announced Health Canada has approved mRESVIA (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the prevention of lower respiratory tract disease ...

U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates Achieved total ...

If you missed the early fall push for flu and COVID-19 vaccines, it's not too late.Health officials say it's important to get ...

Aerobic exercise has been linked with Parkinson's disease progression and risk. (Washington Post) Air purifiers in ...

and Novavax says additional data – including on manufacturing – will be submitted in the second quarter. A US trial is also ongoing and should read out in a few weeks. UK Health Secretary Matt ...